Symbols / ATXI
ATXI Chart
About
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; and intravenous tramadol for the treatment of post-operative acute pain. It also develops BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 897.76K |
| Enterprise Value | -4.07M | Income | -3.74M | Sales | 1.40M |
| Book/sh | 1.12 | Cash/sh | 1.17 | Dividend Yield | — |
| Payout | 0.00% | Employees | 2 | IPO | — |
| P/E | 0.37 | Forward P/E | -0.09 | PEG | — |
| P/S | 0.64 | P/B | 0.25 | P/C | — |
| EV/EBITDA | — | EV/Sales | -2.90 | Quick Ratio | 2.61 |
| Current Ratio | 2.62 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | 0.77 | EPS next Y | -3.14 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2024-11-14 16:00 | ROA | -77.30% |
| ROE | -191.15% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -279.70% | Profit Margin | -266.67% | Shs Outstand | 3.18M |
| Shs Float | 2.75M | Short Float | 2.83% | Short Ratio | 0.65 |
| Short Interest | — | 52W High | 1.34 | 52W Low | 0.15 |
| Beta | -0.50 | Avg Volume | 4.69K | Volume | 2.38K |
| Target Price | — | Recom | None | Prev Close | $0.28 |
| Price | $0.28 | Change | 0.71% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.28
Latest analyst target
3. DCF / Fair value
$-5.36
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.28
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-12-11 | init | Maxim Group | — → Buy | $1 |
| 2023-04-03 | init | Aegis Capital | — → Buy | $32 |
- Rare muscle disease drug deal: Avenue backs ATX-04 for Pompe - Stock Titan Mon, 23 Feb 2026 13
- Avenue Therapeutics Licenses ATX-04 for Pompe Disease - TipRanks Mon, 23 Feb 2026 21
- Avenue (OTC: ATXI): Axsome to acquire Baergic; up to $82M milestones, royalties - Stock Titan hu, 06 Nov 2025 08
- AVENUE THERAPEUTICS, INC. SEC 10-Q Report - TradingView hu, 13 Nov 2025 08
- Avenue Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com Fri, 29 Nov 2024 08
- ATXI Stock Earnings: Avenue Therapeutics Beats EPS for Q4 2023 - TradingView ue, 19 Mar 2024 07
- Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire hu, 14 Nov 2024 08
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace Mon, 11 Mar 2024 07
- Trillium (TRIL) to be Acquired by Pfizer for $2.3 Billion - Yahoo Finance ue, 24 Aug 2021 07
- Avenue Therapeutics Sells Baergic Bio to Axsome - TipRanks Wed, 12 Nov 2025 08
- Why Fortress Biotech Stock Is Plunging Today - The Motley Fool Mon, 12 Oct 2020 07
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday - InvestorPlace hu, 02 Nov 2023 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 111209 | — | — | Stock Award(Grant) at price 0.00 per share. | FORTRESS BIOTECH, INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2026-01-02 00:00:00 | D |
| 1 | 33724 | — | — | Stock Award(Grant) at price 0.00 per share. | FORTRESS BIOTECH, INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-03-31 00:00:00 | D |
| 2 | 23 | 46 | — | Sale at price 2.00 per share. | HERSKOWITZ NEIL | Director | — | 2024-12-02 00:00:00 | D |
| 3 | 61 | 137 | — | Sale at price 2.24 per share. | KRANZLER JAY D | Director | — | 2024-11-05 00:00:00 | D |
| 4 | 500 | 1250 | — | Purchase at price 2.40 - 2.50 per share. | KRANZLER JAY D | Director | — | 2024-09-30 00:00:00 | D |
| 5 | 170000 | — | — | Stock Award(Grant) at price 0.00 per share. | MACLEAN ALEXANDRA M.D. | Chief Executive Officer | — | 2024-09-23 00:00:00 | D |
| 6 | 65000 | — | — | Stock Award(Grant) at price 0.00 per share. | JIN DAVID | Chief Operating Officer | — | 2024-09-23 00:00:00 | D |
| 7 | 413507 | — | — | Stock Award(Grant) at price 0.00 per share. | FORTRESS BIOTECH, INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2024-04-16 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -11.11M | -14.41M | -8.02M | -3.73M |
| TotalUnusualItems | -589.00K | 4.26M | 5.58M | |
| TotalUnusualItemsExcludingGoodwill | -589.00K | 4.26M | 5.58M | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -11.65M | -10.38M | -3.55M | -3.73M |
| EBITDA | -11.70M | -10.16M | -2.44M | -3.73M |
| EBIT | -11.70M | -10.16M | -2.44M | -3.73M |
| NetInterestIncome | 176.00K | -206.00K | -1.14M | 7.00K |
| InterestExpense | 0.00 | 332.00K | 1.16M | 0.00 |
| InterestIncome | 176.00K | 126.00K | 20.00K | 7.00K |
| NormalizedIncome | -11.06M | -14.63M | -9.13M | -3.73M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -11.65M | -10.38M | -3.55M | -3.73M |
| TotalExpenses | 11.28M | 14.54M | 8.04M | 3.74M |
| TotalOperatingIncomeAsReported | -11.28M | -14.54M | -8.04M | -3.74M |
| DilutedAverageShares | 1.30M | 141.22K | 29.14K | 15.11K |
| BasicAverageShares | 1.30M | 141.22K | 29.14K | 15.11K |
| DilutedEPS | -15.79 | -73.48 | -122.25 | -246.75 |
| BasicEPS | -15.79 | -73.48 | -122.25 | -246.75 |
| DilutedNIAvailtoComStockholders | -11.65M | -10.38M | -3.55M | -3.73M |
| NetIncomeCommonStockholders | -11.65M | -10.38M | -3.55M | -3.73M |
| NetIncome | -11.65M | -10.38M | -3.55M | -3.73M |
| MinorityInterests | 44.00K | 111.00K | 51.00K | 0.00 |
| NetIncomeIncludingNoncontrollingInterests | -11.70M | -10.49M | -3.60M | -3.73M |
| NetIncomeContinuousOperations | -11.70M | -10.49M | -3.60M | -3.73M |
| PretaxIncome | -11.70M | -10.49M | -3.60M | -3.73M |
| OtherIncomeExpense | -589.00K | 4.26M | 5.58M | |
| GainOnSaleOfSecurity | -589.00K | 4.26M | 5.58M | |
| NetNonOperatingInterestIncomeExpense | 176.00K | -206.00K | -1.14M | 7.00K |
| InterestExpenseNonOperating | 0.00 | 332.00K | 1.16M | 0.00 |
| InterestIncomeNonOperating | 176.00K | 126.00K | 20.00K | 7.00K |
| OperatingIncome | -11.28M | -14.54M | -8.04M | -3.74M |
| OperatingExpense | 11.28M | 14.54M | 8.04M | 3.74M |
| ResearchAndDevelopment | 6.64M | 10.36M | 2.70M | 1.25M |
| SellingGeneralAndAdministration | 4.64M | 4.18M | 5.34M | 2.48M |
| GeneralAndAdministrativeExpense | 4.64M | 4.18M | 5.34M | 2.48M |
| OtherGandA | 4.64M | 4.18M | 5.34M | 2.48M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 2.11M | 341.30K | 63.65K | 18.75K |
| ShareIssued | 2.11M | 341.30K | 63.65K | 18.75K |
| TangibleBookValue | 2.80M | 1.58M | 3.90M | 3.45M |
| InvestedCapital | 2.80M | 1.58M | 3.90M | 3.45M |
| WorkingCapital | 1.86M | 654.00K | 3.27M | 3.45M |
| NetTangibleAssets | 2.80M | 1.58M | 3.90M | 3.45M |
| CommonStockEquity | 2.80M | 1.58M | 3.90M | 3.45M |
| TotalCapitalization | 2.80M | 1.58M | 3.90M | 3.45M |
| TotalEquityGrossMinorityInterest | 1.86M | 654.00K | 3.27M | 3.45M |
| MinorityInterest | -941.00K | -928.00K | -639.00K | 0.00 |
| StockholdersEquity | 2.80M | 1.58M | 3.90M | 3.45M |
| RetainedEarnings | -102.58M | -90.93M | -80.55M | -77.00M |
| AdditionalPaidInCapital | 105.38M | 92.51M | 84.46M | 80.45M |
| CapitalStock | 0.00 | 3.00K | 0.00 | 0.00 |
| CommonStock | 0.00 | 3.00K | 0.00 | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 816.00K | 1.20M | 3.58M | 509.00K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 816.00K | 1.20M | 3.58M | 509.00K |
| OtherCurrentLiabilities | 16.00K | 586.00K | 2.61M | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 18.00K | 11.00K | 199.00K | 24.00K |
| PayablesAndAccruedExpenses | 782.00K | 599.00K | 771.00K | 485.00K |
| CurrentAccruedExpenses | 481.00K | 198.00K | 621.00K | 123.00K |
| Payables | 301.00K | 401.00K | 150.00K | 362.00K |
| DuetoRelatedPartiesCurrent | 146.00K | 323.00K | 21.00K | 58.00K |
| AccountsPayable | 155.00K | 78.00K | 129.00K | 304.00K |
| TotalAssets | 2.67M | 1.85M | 6.84M | 3.96M |
| TotalNonCurrentAssets | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 2.67M | 1.85M | 6.84M | 3.96M |
| OtherCurrentAssets | 78.00K | 67.00K | 137.00K | 107.00K |
| PrepaidAssets | 107.00K | |||
| Receivables | 0.00 | 90.00K | ||
| DuefromRelatedPartiesCurrent | 0.00 | 90.00K | ||
| CashCashEquivalentsAndShortTermInvestments | 2.59M | 1.78M | 6.71M | 3.76M |
| CashAndCashEquivalents | 2.59M | 1.78M | 6.71M | 3.76M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -9.03M | -12.45M | -7.60M | -3.75M |
| RepurchaseOfCapitalStock | 0.00 | -1.10M | 0.00 | |
| IssuanceOfCapitalStock | 1.62M | 7.53M | 11.50M | 5.04M |
| CapitalExpenditure | -3.00M | |||
| EndCashPosition | 2.59M | 1.78M | 6.71M | 3.76M |
| BeginningCashPosition | 1.78M | 6.71M | 3.76M | 3.13M |
| ChangesInCash | 811.00K | -4.92M | 2.94M | 631.00K |
| FinancingCashFlow | 9.84M | 7.53M | 10.54M | 4.38M |
| CashFlowFromContinuingFinancingActivities | 9.84M | 7.53M | 10.54M | 4.38M |
| NetOtherFinancingCharges | -1.21M | -508.00K | -663.00K | |
| ProceedsFromStockOptionExercised | 9.42M | 1.00K | 148.00K | 0.00 |
| NetCommonStockIssuance | 1.62M | 7.53M | 10.39M | 5.04M |
| CommonStockPayments | 0.00 | -1.10M | 0.00 | |
| CommonStockIssuance | 1.62M | 7.53M | 11.50M | 5.04M |
| InvestingCashFlow | 0.00 | -3.00M | 0.00 | 0.00 |
| CashFlowFromContinuingInvestingActivities | 0.00 | -3.00M | 0.00 | 0.00 |
| NetIntangiblesPurchaseAndSale | 0.00 | -3.00M | 0.00 | 0.00 |
| PurchaseOfIntangibles | 0.00 | -3.00M | 0.00 | 0.00 |
| OperatingCashFlow | -9.03M | -9.45M | -7.60M | -3.75M |
| CashFlowFromContinuingOperatingActivities | -9.03M | -9.45M | -7.60M | -3.75M |
| ChangeInWorkingCapital | 179.00K | -290.00K | 408.00K | -461.00K |
| ChangeInPayablesAndAccruedExpense | 190.00K | -360.00K | 348.00K | -377.00K |
| ChangeInPrepaidAssets | -11.00K | 70.00K | -30.00K | 6.00K |
| ChangeInReceivables | 0.00 | 90.00K | -90.00K | |
| OtherNonCashItems | 666.00K | 4.68M | 530.00K | |
| StockBasedCompensation | 1.24M | 906.00K | 649.00K | 442.00K |
| OperatingGainsLosses | 589.00K | -4.26M | -5.58M | |
| GainLossOnInvestmentSecurities | 589.00K | -4.26M | -5.58M | |
| NetIncomeFromContinuingOperations | -11.70M | -10.49M | -3.60M | -3.73M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ATXI
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|